Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Molecular Testing in Breast Cancer

October 6th 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

Dr Haffty on the Feasibility of Preoperative Radiation Boost in Breast Cancer

October 5th 2023

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

SABR to Oligoprogressive Lesions Delays Systemic Therapy Change in ER+ Advanced Breast Cancer

October 5th 2023

Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.

Reduced-Dose and Partial-Breast Radiotherapy Sustain Long-Term Safety and Efficacy in Early-Stage Breast Cancer

October 4th 2023

Treatment with reduced-dose or partial-breast radiotherapy sustained long-term safety and elicited similar rates of ipsilateral breast tumor relapse compared with whole-breast radiotherapy in patients with early-stage breast cancer.

Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer

October 4th 2023

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Preoperative S-PBI Plus Endocrine Therapy is Safe, Produces Responses in Early-Stage ER+ Breast Cancer

October 4th 2023

Ablative preoperative stereotactic partial breast irradiation plus endocrine therapy was safe at a single fraction of 34 Gy and generated pathological complete responses and near complete responses in patients with early-stage, estrogen receptor-positive breast cancer.

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC

October 3rd 2023

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.

Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC

October 3rd 2023

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

October 2nd 2023

Patients with breast cancer who received hypofractionated postmastectomy radiotherapy experienced similar toxicities vs those who received conventionally fractionated postmastectomy radiotherapy, according to a presentation shared at the 2023 American Society for Radiation Oncology Annual Meeting.

Mechanisms of Action of Antibody-Drug Conjugates

September 29th 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

Overview of Antibody-Drug Conjugates (ADCs)

September 29th 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.

Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast Cancer

September 27th 2023

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes

September 27th 2023

Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

September 26th 2023

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC

September 26th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, Diaz review the available safety and efficacy data from the TROPiCS-02 trial on the use of antibody drug conjugate sacituzumab govitecan for the treatment of HR+/HER2- metastatic breast cancer.

Utility of Primary Tumor Surgery for De Novo Metastatic Breast Cancer

September 26th 2023

Experts debate the utility of surgery on the primary tumor in patients with novel metastatic HR+/HER- breast cancer.

Case Presentation: A 56-Year-Old Woman With ER+/HER2- mBC

September 26th 2023

Virginia Kaklamani, MD, presents the case of a 56-year-old postmenopausal woman diagnosed with ER+/HER2- metastatic breast cancer for discussion.

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Ezra Rosen, MD, PhD, highlights the early-phase investigation of zotatifin in estrogen receptor-positive metastatic breast cancer, explains the agent’s unique mechanism of action as well as its efficacy and safety in a heavily pretreated population, and underscores the need for improved sequencing of the myriad of treatment options in the post–CDK4/6 inhibitor space.

Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast Cancer

September 22nd 2023

Judy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.